Trial Profile

A Randomized, Multi-dose, Controlled Trial Investigating the Efficacy, Safety and Tolerability, and Pharmacokinetics of Exenatide Once Monthly Suspension

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 17 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Exenatide (Primary)
Indications Type 2 diabetes mellitus
Focus Therapeutic Use
Sponsors AstraZeneca

Most Recent Events

19 Jul 2016 Primary endpoint of mean change in HbA1c from baseline over week 20 has not been met, according to results published in the Diabetes Care.
19 Jul 2016 Results published in the Diabetes Care
16 Sep 2011 Results presented at the 47th Annual Meeting of the European Association for the Study of Diabetes.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com